Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CE8-H82E9 | Human | Biotinylated Human CEACAM-8 / CD66b Protein, His,Avitag™ (SPR verified) |  |
|
|
| CE8-H5224 | Human | Human CEACAM-8 / CD66b Protein, His Tag |  |
|
|
Immobilized Human CEACAM-8, His Tag (Cat. No. CE8-H5224) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-6, His,Avitag (Cat. No. CE6-H82E7) with a linear range of 0.078-1.25 μg/mL (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Besilesomab | BW-250-183; 99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx | Approved | Cis Bio International Sa | Scintimun | EU | Osteomyelitis | Cis Bio International Sa | 2010-01-11 | Osteomyelitis | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| 90Y-DTPA-besilesomab | TLX-66 | Phase 2 Clinical | Telix Pharmaceuticals Ltd | Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell | Details |
This web search service is supported by Google Inc.
A-Z
